Evidence map›Paper›PMID 41009531›Full record

ArticleInternational journal of molecular sciences2025

Molecular Features and Actionable Gene Targets of Testicular Germ Cell Tumors in a Real-World Setting.

Rafael Morales-Grimany, Krinio Giannikou, Cesar Delgado, Kshitij Pandit, Fady Baky, Armon Amini, Kit Yuen, Thomas Gerald, Rohit Badia, Jacob Taylor and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rafael Morales-GrimanyDepartment of Medicine, School of Medicine, Universidad Central del Caribe, Bayamon, PR 00956, USA.
Krinio GiannikouDepartment of Urology, Moores Cancer Center, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Cesar DelgadoDepartment of Urology, Moores Cancer Center, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Kshitij PanditDepartment of Urology, Moores Cancer Center, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Fady BakyDepartment of Urology, School of Medicine, University of Texas Southwestern, Dallas, TX 75390, USA.
Armon AminiDepartment of Urology, School of Medicine, University of Texas Southwestern, Dallas, TX 75390, USA.
Kit YuenDepartment of Urology, Moores Cancer Center, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Thomas GeraldDepartment of Urology, School of Medicine, University of Texas Southwestern, Dallas, TX 75390, USA.ORCID 0000-0002-8877-6799
Rohit BadiaDepartment of Urology, School of Medicine, University of Texas Southwestern, Dallas, TX 75390, USA.ORCID 0000-0001-6134-1237
Jacob TaylorDepartment of Urology, School of Medicine, University of Texas Southwestern, Dallas, TX 75390, USA.
Luke WangDepartment of Urology, Moores Cancer Center, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Juan Javier-DeslogesDepartment of Urology, Moores Cancer Center, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Vitaly MargulisDepartment of Urology, School of Medicine, University of Texas Southwestern, Dallas, TX 75390, USA.
Solomon WolduDepartment of Urology, School of Medicine, University of Texas Southwestern, Dallas, TX 75390, USA.
Amirali SalmasiDepartment of Urology, Moores Cancer Center, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Fred MillardDepartment of Medicine, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Rana R MckayDepartment of Medicine, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Aditya BagrodiaDepartment of Urology, Moores Cancer Center, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-3358-1193

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular profiling of testicular germ cell tumors (TGCTs) provides critical insights into personalized treatment approaches, particularly for patients with recurrent or treatment-resistant disease. In this study, we retrospectively analyzed clinicopathological and targeted genomic sequencing data from 27 TGCT patients, including 7 seminomas, 19 non-seminomas, and 1 prepubertal type teratoma, across stage I (48%), stage II (41%), and stage III (11%). Tumor samples were obtained from 27 orchiectomies, with additional pathological specimens collected from 16 of these patients during retroperitoneal lymph node dissections (RPLNDs); these included 8 chemotherapy-naïve and 8 post-chemotherapy cases. The median tumor mutational burden (TMB) was 0.5 mutations/Mb, consistent with the low mutation rate typically observed in TGCTs. Somatic mutations and copy number gain alterations were detected in 56% (15/27) of patients, primarily in

Indexed as

Biomarkers, TumorNeoplasms, Germ Cell and EmbryonalTesticular NeoplasmsAdolescentAdultDNA Copy Number VariationsHumansMaleMiddle AgedMutationRetrospective StudiesYoung AdultBiomarkers, Tumorchemoresistanceembryonal carcinomamutationsseminomatargeted therapyteratoma

Identifiers

PMID41009531
PMCPMC12469615

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.